Navigation Links
Chemotherapy Induced Nausea and Vomiting (CINV) Existing and Pipeline Drugs Market is Expected to Reach USD 2.1 Billion Globally in 2018: Transparency Market Research
Date:11/28/2012

ALBANY, New York, November 28, 2012 /PRNewswire/ --

According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron FDC, APF530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018," the global CINV market was worth USD 1.3 billion in 2011 and is expected to reach USD 2.1 billion in 2018, growing at a CAGR of 7.1% from 2013 to 2018. The North American CINV existing and pipeline drugs market is expected to reach USD 1.0 billion in 2018. Sluggish economic growth and a poor reimbursement scenario in European countries have hampered the growth of CINV drugs market in these regions.

.

Browse the full report at http://www.transparencymarketresearch.com/cinv-market.html

Nausea and vomiting represent the most frequent side-effects experienced by chemotherapy patients, referred to as chemotherapy-induced nausea and vomiting (CINV), which is debilitating to cancer patients. Emetogenic refers to the likelihood of a chemotherapy drug affecting the patient in an adverse manner, leading to added illness or sickness. Highly emetogenic chemotherapy (HEC) mostly leads to nausea and vomiting in 90% or more of the cases, while moderately emetogenic chemotherapy (MEC) causes nausea and vomiting in 30-90% of the cases.

Current drug treatments available to prevent CINV have failed to completely overcome the symptoms of this disease. Moreover, most of the drugs are approved for acute-onset CINV whereas there is no drug approved yet for delayed-onset CINV for patients receiving HEC, which occurs more frequently (50-70% of patients) in the cancer population. The inefficiency to effective
'/>"/>

SOURCE Transparency Market Research
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
2. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
3. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
4. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
5. First-of-its-kind self-assembled nanoparticle for targeted and triggered thermo-chemotherapy
6. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
7. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
8. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
9. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
10. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
11. Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Mass. , June 2, 2015 /PRNewswire/ ... a biotechnology company focused on discovering and ... of dermatology and ophthalmology, today announced that Dr. ... Officer, will present at the 23 rd ... six-day world congress will include in-depth presentations ...
(Date:6/2/2015)... 02, 2015 Through rare discovery of ... Yancy Corporation is enabling World Scientists to actually ... biological sample, displaying the full nature (position, shape, size, ... , Jeff Porter, Co-Founder of the Yancy Corporation, says, ... – rare. They come once in a lifetime, if ...
(Date:6/1/2015)... 02, 2015 Chosen for his ... Jack Uldrich has been selected as keynote speaker ... today. He will deliver his keynote: "Don't Stop ... delivered presentations to the American Medical Association, Blue ... Neurology, Alcetel-Lucent/Verizon Forum on Wireless Healthcare, United Healthcare, ...
(Date:6/1/2015)... RARITAN, N.J. , June 1, ... announced data from the Phase 3 multicenter study ... survival (PFS) with trabectedin (YONDELIS ® ) compared ... or leiomyosarcoma (LMS) previously treated with an anthracycline ... is the largest randomized Phase 3 study ever ...
Breaking Biology Technology:RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... Madison, Wis. - Quintessence Biosciences , a ... one of its EVade cancer treatments, has been selected ... ,Quintessence said that pending a favorable preclinical safety assessment, ... Drug Administration an investigational new drug application in ...
... adison, Wis. - Five years removed from ... investors and questioning the value of the online world, ... The models are both progressive in their cutting-edge approach ... realities. , ,The picture of those business models ...
... - If you dropped the word sustainability in ... of them would have pegged you as an aging ... riding their bikes to work. , ,Today, sustainability still ... might stick around to talk because there's no avoiding ...
Cached Biology Technology:Web-centric entrepreneurs find models that attract investment 2Web-centric entrepreneurs find models that attract investment 3Web-centric entrepreneurs find models that attract investment 4Web-centric entrepreneurs find models that attract investment 5Re-engineering our economy to be sustainable and profitable 2Re-engineering our economy to be sustainable and profitable 3Re-engineering our economy to be sustainable and profitable 4
(Date:5/28/2015)... ALLEN, Va. , May 28, 2015 /PRNewswire/ ... the release of a new report titled "Markets ... materials (reversible polymers, inorganic capsule and vascular systems, ... coatings) will grow to around $2.7 billion by ... deliverable from n-tech,s extensive coverage of smart materials. Other ...
(Date:5/22/2015)... , May 22, 2015 ... Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software ... User (Government and Utilities, Consumer and Home) - Global ... to grow from $2.77 Billion in 2015 to $6.19 ... Browse 79 market data Tables and   ...
(Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... In the perilous hours immediately after birth, a newborn ... from its mother. Under normal circumstances, newborns mount a ... This survival response involves a process of controlled breakdown ... has been well documented, the key mechanistic regulators of ...
... University today announced the discovery of an underlying genetic cause ... infancy that also affects millions of adults around the world ... were just published in PLoS ONE , a professional ... to this frustrating syndrome, which is difficult to treat and ...
... frequently causes gastric ulcers and is also one of the ... infection is also associated with another gastric cancer risk factor, ... Clinical Investigation , researchers led by Richard Peek at Vanderbilt ... -induced gastric cancer. Peek and colleagues found that low iron ...
Cached Biology News:Nutrient-sensing enzymes key to starvation response and survival in newborn mammals 2Researchers discover genetic basis for eczema, new avenue to therapies 2Ironing out the link between H. pylori infection and gastric cancer 2
... polyclonal to JMJD2D ( Abpromise for ... Synthetic peptide conjugated to KLH derived ... Human JMJD2D.(Note: the amino acid sequence is ... Entrez Gene ID: 55693 ...
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Biology Products: